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Introduction 
Glioma is the most common form of primary brain 
tumours in adults and it could be highly malignant [1]. 
Glioma is characterised by diffused infiltration, 
increased angiogenesis, resistance to apoptosis, 
necrogenesis as well as genomic instability [1]. 
Traditionally, glioma is classified according to the 
World Health Organisation (WHO) grading scale, 
which was last revised in 2007 [2]. However, many 
histologically indistinguishable tumours exhibit their 
own discrete clinical course and outcome with similar 
treatment modality. Thus, prediction of prognosis and 
response to therapy may not be accurate based purely 
on histopathological classification [3]. Despite 
therapies such as surgical resection, radiotherapy and 
chemotherapy, the median survival of patients with 
glioma is between 12 – 15 months [4]. Hence, 
molecular genotyping is crucial in order to achieve 
reliable diagnostic and therapeutic improvement in 
glioma patients [4]. Molecular genotyping would also 
be beneficial to both clinicians and patients in 
reducing the heterogeneous admixture and in focusing 
on accurately classified cases for targeted therapy 
using investigational new drugs based on their 
molecular signatures. Based on the molecular and 
genomic characterisation, glioma can be classified into 
low and high grade gliomas [5,6]. Low grade gliomas 
(I and II) are asymptomatic and grows slowly. In 
contrast, high grade glioma (III and IV) is the lethal 
type where tumour cells could diffuse into the normal 
cerebral cortex and could lead to death. The prognosis 
of the high grade glioma is poor compared to the low 
grade glioma. Several predictive markers have been 
identified for the diagnosis and prognostication of 
glioma and are currently on their way into clinical 
applications [4, 7-9]. For instance, tumours that harbor 
IDH1 mutation are sensitive to temozolomide (TMZ) 
in low-grade glioma [10]. The IDH1 is now used as a 
 
 
Identification of missense mutations in genes related to  
cancer pathways in glioma 
 
 
1Nor Azian Abdul Murad, 1Saiful Effendi Syafruddin, 1Muhiddin Ishak, 1Mohd Ridhwan Abdul Razak, 1Sri 
Noraima Othman, 1, 2Soon Bee Hong, 2Azizi Abu Bakar, 2Farizal Fadzil, 2Jegan Thanabalan, 2Toh Charng Jeng, 
3Isa Mohamed Rose, 1,4Roslan Harun, 1Rahman Jamal 
 
1UKM Medical Molecular Biology Institute (UMBI); 2Department of Surgery, Faculty of Medicine; 3Department 
of Pathology, Faculty of Medicine; 4Department of Medicine, Faculty of Medicine, UKM, Cheras, Kuala 
Lumpur, Malaysia 
 
Received on 15/03/2015 / Accepted on 08/09/2015 
 
Abstract 
 
Glioma is the most common primary brain tumour of the central nervous system. Many genetic alterations 
and mutations have been identified in glioma using various approaches. We performed DNA sequencing on 
the tumours of 16 patients with Grade I, II, III and IV glioma. The AmpliSeq Cancer Primers Pool was used 
to generate the amplicons. The targeted-ion sphere particles were prepared using the Ion One Touch and 
Ion Enrichment systems. DNA sequencing was performed on the Ion Torrent Personal Genome Machine 
(PGM) and the data were analysed using the Torrent Suite Software.  
In total, 14 mutations were identified in the following genes: KDR (Q472H), MLH1 (V384D), MET (N375S), 
PTPN11 (E69K), BRAF (V600E), TP53 (D149E, E154K, V157F), IDH1 (R132H), PIK3CA (H1047R), CSF1R 
(c1061_1061 ins A), KIT (M541L), PTEN (c1373_1373 del A) and PDGFRA (E556V). In addition, there were 
four novel mutations identified; TP53 (E154K, and D149E), CSF1R (c1061_1061 ins A) and PDGFRA 
(E556V). The pathogenicity prediction showed that only three mutations were pathogenic: PTPN11 (E69K), 
BRAF (V600E) and Tp53 (E154K). These mutations result in changes of the proteins’ structure and could 
affect their functions. Pathway analyses suggested that these genes are closely related to the pathogenesis of 
GBM through several pathways such as proliferation and invasion, metabolism and angiogenesis. 
In conclusion, PGM in combination with the AmpliSeq Cancer Panel could be utilised as a potential 
molecular diagnostic tool not only for glioma but also for other cancers. 
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diagnostic marker for diffuse grade I and III gliomas 
as well as secondary GBM, and the presence of 
mutation is associated with a better prognosis [4].  In 
addition, mutations in the mismatch repair gene 
(MMR) such as MSH6 mediate TMZ resistance (11). 
Tumours with hypermethylation of the O-6 
methylguanine-DNA-methyltransferase (MGMT) 
promoter may also develop resistance to TMZ therapy 
by gaining a hypermutator phenotype and mutations in 
the MMR gene [11]. However, combination between 
TMZ therapy and radiotherapy significantly increase 
the survival of patients’ with methylated MGMT 
promoter when compared to patients who lacked 
MGMT promoter hypermethylation [12]. Rapid 
advancement in sequencing technologies have enabled 
researchers to perform whole-genome sequencing, 
targeted sequencing, and other applications using the 
next-generation sequencing [13]. Recently, several 
bench-top sequencing machines such as the Ion 
Torrent (Life Technologies, USA) or MiSeq (Illumina 
Inc., USA) have been launched to sequence small 
genomes such as bacteria genomes, as well as for 
targeted sequencing [14]. These NGS platforms allow 
mutational screening to be performed in a single day 
where a number of genes could be simultaneously 
sequenced with high accuracy [14]. The Ion Torrent 
Personal Genome Machine (PGM) in combination 
with the Ion AmpliSeq Cancer Panel are able to 
generate high-throughput screening of over 44 tumour 
suppressor genes and oncogenes which are frequently 
cited and mutated using a single-tube multiplex PCR 
assay with a small amount of starting DNA. Despite 
the knowledge and known mutations that have been 
detected in studies conducted in Western populations, 
the frequency and type of mutations in glioma patients 
from this region of the world has not been fully 
elucidated. Therefore, the aim of this study was to 
characterise the mutations involved in glioma patients 
in Malaysia population by using the PGM. The study 
may provide an insight into the pathogenesis of glioma 
in our population and could possibly be used for rapid 
molecular screening of glioma patients for a more 
detailed and accurate risk stratification. 
 
Materials and methods 
 
Patients and tumour specimens 
 
All patients with primary brain tumour confirmed by 
diagnostic imaging techniques and underwent surgical 
excision at the Universiti Kebangsaan Malaysia 
Medical Centre (UKMMC) between the year 2010 and 
2012 were included. Approval to conduct the research 
was obtained from the UKM Research Ethics 
Committee (UKM1.5.3.5/244/SPP/UMBI-001-2011). 
After informed consent, the demographic particulars 
and clinical data of the enrolled patients were 
recorded. For each patient, a section of the tumour 
specimens was collected and snap-frozen in liquid 
nitrogen immediately upon tumour excision in the 
operating theatre. Histopathological examination 
(HPE) was performed by an experienced pathologist 
to exclude non-gliomas and to classify the glioma 
samples according to WHO grading. Specimens were 
also frozen-sectioned and H&E staining was 
performed for confirmation of 80% representation by 
another pathologist prior to DNA extraction. Tumour 
location was determined by magnetic resonance 
imaging (MRI) scan before surgery. In total, 16 glioma 
patients (grade I, II, III, and IV) were included in this 
study. 
The demographic and clinical data of these patients are 
shown as in Table 1. 
 
DNA isolation 
 
DNA samples were isolated from 15mg tumour tissue 
using the QIAamp DNA Mini Kit (Qiagen, Germany). 
The quality and quantity of the DNA were determined 
using NanoDrop (Thermo Scientific, USA) and Qubit 
Fluorometric Quantitation, Double Stranded DNA 
Broad  Range Assay kit (Invitrogen, USA) 
respectively. The DNA samples were diluted to 1.67 
ng/μL for library preparation. 
 
Library preparation 
 
The AmpliSeq Cancer Panel which contains 190 
primer pairs covering 44 common cancer-related 
genes was used for library amplification (Life 
Technologies, USA). The DNA was amplified using 
the 5X Ion AmpliSeqTM Primer Pool and the 5X Ion 
AmpliSeqTMHiFi Master Mix. The primers were 
partially digested using the FuPa reagent. 
Subsequently, adapters were ligated into the DNA 
sequences using the Switch solution, Ion AmpliSeq 
adapters, and DNA ligase. The samples were purified 
using Agent Court AMPure XP reagent (BD 
Biosciences, USA). The library was subjected to a 
second-round amplification using the Platinum PCR 
SuperMix High Fidelity, and Library Amplification 
Primer Mix. The amplified library was subjected to a 
two-round purification process using Agent Court 
AMPure XP reagent. Quantification of the library was 
performed on the AgilentTM Bioanalyzer instrument 
using the Agilent High Sensitivity DNA Kit (Agilent, 
Technologies, USA). 
 
Template ion sphere particle (ISP) preparation using 
Ion One Touch System 
 
The template ISP was prepared using the Ion One 
Touch Instrument. The Ion One TouchTM 200 
Template kit protocol was utilized to prepare the 
Nor Azian Abdul Murad et al.                    Asia, Pac. J. Mol. Med 
3 
enriched template ISPs (Life Technologies, USA). 
Briefly, 10 - 20 pmol of the library was used to prepare 
the template ISP using the Ion One TouchTM 2X 
Reagent Mix, Enzyme Mix, and Ion One Touch 
Sphere Particles. Subsequently, the enriched template 
ISP was prepared using the Ion One TouchTM 
enrichment system. For quality control (QC), 
unenriched and enriched template ISPs was subjected 
to Qubit measurement to assess the polyclonal 
molecules. Only samples that passed the QC (% 
unenriched ISP <30% and % enriched template ISP 
>80%) were subjected to PGM sequencing.  
 
PGM sequencing and data analysis 
 
The sequencing run was performed according to the 
Ion Torrent PGM manual and the data generated were 
analysed using the Ion Torrent Suite software (Life 
Technologies, USA). The mutations were called using 
the Integrated Genome Variation software and 
confirmed with the SNPEFF software 
(http://snpeff.sourceforge.net/download.html#install).  
The patients’ data were compared to the hg19 
database. 
 
Prediction of mutation pathogenicity 
 
The Piezoelectric Micro Machine Ultrasonic 
Transducers (PMut) software which uses the neural 
network (NN) algorithm was applied to predict the 
pathogenicity of a particular mutation 
(http://mmb2.pcb.ub.es:8080/PMut) [15]. The neural 
network (NN) predicts the outcome of a particular 
mutation using different types of sequence 
information to label the mutations and subsequently 
process the information.  A mutation is predicted to be 
pathogenic when the NN output is >0.5 [15]. 
 
Protein prediction tools 
 
The protein sequence and transcripts for selected 
genes including PTPN II, BRAF and TP53 were 
retrieved from NCBI database, UniPROT, and Protein 
Data Bank (PDB). The variant and functional effects 
were determined using the Variant Effect Predictor 
(http:///www.ensembl.org/info/docs/variation/vep/ind
ex.html) [16], PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/index.shtml) 
[17], Basic Local Alignment Search Tool (BLAST) as 
well as SIFT (http://sift.bii.a-star.edu.sg/) [18] and 
SNAP (http://sift.bii.a-star.edu.sg/) softwares [19]. 
The protein stability was predicted using MuPro 
software (http://mupro.proteomics.ics.uci.edu/). The 
amino acid properties, protein function and structure 
as well as their 3D protein structure for mutated gene 
were analysed (please change all to UK spelling) using 
Project HOPE web based tool 
(http://www.cmbi.ru.nl/hope/home). 
 
Validation using Sanger sequencing 
 
Samples with mutations were validated using the 
Sanger sequencing method. Primers from the 
AmpliSeq Cancer Panel for the selected validation 
were used for Sanger sequencing. Briefly, PCR 
products were generated and cycle sequencing was 
performed using the Big Dye Terminator V3.1 reagent 
(Life Technologies, USA). The cycle sequencing 
products were then processed using ethanol 
precipitation and sequencing was carried out using the 
ABI 3100 capillary electrophoresis (Life 
Technologies, USA). The results were analysed using 
Basic Local Alignment System Tool (BLAST). New 
primers were designed for the validation in cases 
where we failed to amplify or sequence using primers 
from the AmpliSeq Cancer Panel. 
 
Validation using TaqMan® Mutation Assay 
 
The small deletion and insertion in the PTEN and 
CSFR1 were validated using Custom TaqMan 
Mutation Assay. The assay was performed according 
to the protocol described by the manufacturer (Life 
Technologies, USA). Mutation was detected using 
allelic discrimination assay analysis. 
 
 
Results 
 
In total, 16 glioma patients were included in this study 
(four patients for each grade). The patients’ age ranged 
between four to 64 years old. 14 patients were males, 
and two were females. Seven patients were Chinese 
whereas nine were Malays. Tumour location and the 
HPE descriptions for these patients are indicated in 
Table 1. Most of the patients are still alive and only 
three patients have died due to the disease. The 
survival of three patients could not be retrieved due to 
default follow-up.  
Table 2 shows the data generated using the Torrent 
Suite software. The number of bases (Mbp) generated 
range between 27.91 Mbp and 47.82 Mbp, which is 
above the detection limit. The identified mutations are 
listed in Table 3. A total of 14 mutations were 
identified and these included 12 missense mutations in 
KDR, MLH1, MET, PTPN11, PDGFRA, BRAF, IDH1, 
PIK3CA, KIT, and TP53 (3 mutations). Two 
frameshift mutations were detected in the CSF1R 
(c1061_1061 ins A) and PTEN (c1373_1373 del A) 
genes. Most of the samples carry more than one 
mutations. These mutations were compared to the 
Catalogue of Somatic Mutations in Cancer (COSMIC) 
in order to search for novel mutations. Four mutations 
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were confirmed to be novel, which included E154K 
and D149E in TP53, the frameshift mutation in CSF1R  
 
 
 
Table 1: Demographic and clinical data of glioma patients involved in the study
WHO 
Grade
Sample ID
Age at 
diagnosis 
(Years)
Age at 
specimen 
collection 
(Years)
Gender Ethnic
New 
case
Tumour 
location
Survival 
(Months)
HPE description
  BT21 4 4 F MY Yes   Suprasellar Alive   Pilocytic astrocytoma
BT49 33 33 M MY Yes Suprasellar Alive Pilocytic astrocytoma
BT54 18 27 M CH No Left optic nerve Alive Pilocytic astrocytoma
BT94 1 1 M MY Yes
Right frontal 
parasagittal
Alive
Desmoplastic infantile 
astrocytoma
  BT31 40 40 M MY Yes
  Deep left 
frontal 
Alive   FirilIary astrocytoma
BT40 30 40 M MY No Right frontal N/A Oligodendroglioma
BT69 23 41 M MY No
Right lateral 
ventrical
Alive Ependymoma
BT98 15 22 M MY No Left parietal Alive
Pleomorphic xanthomatous 
astrocytoma
  BT7 10 10 M CH Yes
  Left basal 
ganglia 
1
  Anaplastic glioma with  clear cell 
ependymoma
BT63 26 31 M MY No Left frontal Alive Anaplaticoligodendroglioma
BT74 14 14 M MY Yes Third ventrical Alive Anaplastic ependymoma
BT108 42 42 M CH Yes Deep bifrontal Alive Anaplaticoligodendroglioma
  BT2 58 58 M CH Yes
 Deep left 
parietal
0.3  Glioblastomamultiforme
BT4 57 57 F CH Yes Left temporal N/A Gliosarcoma
BT8 61 61 M CH No Right temporal 8.5 Glioblastomamultiforme
BT10 64 64 M CH Yes
Left temporo-
occipital
N/A Glioblastomamultiforme
*(F: Female; M: Male; MY: Malay; CH: Chinese; N/A: Not available (Default follow up); HPE: Histopathological Examination)
1
2
3
4
Table 2: Data generated from the Personal Genome Machine sequencing of glioma patients
No Samples
Total number of bases 
(Mbp)
No of Q20 bases 
(Mbp)
Total no of reads
Mean length 
(bp)
Longest read 
(bp)
1 21T_GI 35.21 32.65 427,573 82 203
2 49T_GI 47.43 44.1 581,998 82 198
3 54T_GI 37.54 35.28 481,598 78 201
4 94T_GI 45.02 40.88 562,787 80 202
5 31T_GII 34.15 31.59 426,942 80 202
6 40T_GII 27.19 24.67 340,375 80 202
7 69T_GII 37.99 34.53 476,121 80 200
8 98T_GII 46.52 43.28 576,446 81 202
9 63T_GIII 47.82 43.43 588,755 81 201
10 74T_GIII 38.31 34.79 478,196 80 202
11 108T_GIII 44.29 41.33 547,250 81 202
12 7T_GIII 45.57 42.06 501,388 91 202
13 10T_GIV 37.98 32 500,490 76 196
14 2T_GIV 43.91 40.45 552,828 79 203
15 4T_GIV 45.04 41.32 560,437 80 202
16 8T_GIV 41.09 43.28 576,446 81 202
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Table 3: Mutations identified in the glioma patients using the Personal Genome Machine 
No Samples Chrom Position Gene Type Ploidy Ref Var
Acid Amino 
changes
Exon
Variant 
Coverage
HotSpotID
1 21T_GI 4 55972974 KDR SNP Het T A Q472H 11 1488 COSM149673
3 37067240 MLH1 SNP Het T A V384D 12 1545 COSM26085
4 55972974 KDR SNP Het T A Q472H 11 2041 COSM149673
7 116340262 MET SNP Het A G N375S 2 1571 COSM710
12 112888189 PTPN11 SNP Het G A E69K 3 2965 COSM13013
7 140453136 BRAF SNP Het A T V600E 15 2918 COSM149673
17 7577082 Tp53 SNP Het C T E154K 4 2852 -
2 209113112 IDH1 SNP Het C T R132H 4 1523 COSM28746
4 55972974 KDR SNP Het T A Q472H 11 932 COSM149673
5 149453048 CSF1R INS Het A AA Frameshift 7 1603 -
5 69T_GII 4 55972974 KDR SNP Het T A Q472H 11 2008 COSM149673
4 55593464 KIT SNP Het A C M541L 10 846 COSM28026
4 55972974 KDR SNP Het T A Q472H 11 1034 COSM149673
COSM476,
7 7T_GIII 10 89624242 PTEN DEL Hom AA A Frameshift 1 73
COSM4937; 
COSM4929
4 55972974 KDR SNP Hom T A Q472H 11 1352 COSM149673
5 149453048 CSF1R INS Het A AA Frameshift 7 1302 -
7 116340262 MET SNP Hom A G N375S 2 5267 COSM710
4 55972974 KDR SNP Hom T A Q472H 11 2196 COSM149673
10 108_GIII 4 55972974 KDR SNP Hom T A Q472H 11 1892 COSM149673
11 2T_GIV 4 55972974 KDR SNP Hom T A Q472H 11 981 COSM149673
17 7577082 TP53 SNP Het C T E154K 4 2482 -
4 551412021 PDGFRA SNP Het A T E556V 12 1579 -
4 55972974 KDR SNP Het T A Q472H 11 1146 COSM149673
(Chrom: Chromosome, Ref: Reference, Var: Variant)
G C D149E 4 3445 -
G H1047R 21 2386 COSM775
17 7577095 TP53 SNP Het
2565 COSM476
13 10T_GIV
3 178952085 PIK3CA SNP Het A
SNP Het A T V600E 15
A V157F 4 1199 COSM10670
12 8T_GIV
7 140453136 BRAF
17 7578461 TP53 SNP Het C
A AA Frameshift 7 470 -
1080
8 63T_GIII
9 74T_GIII
5 149453048 CSF1R INS Het
SNP Het A T V600E 15
G H1047R 21 3975 COSM775,
6 98T_GII
7 140453136 BRAF
3 178952085 PIK3CA SNP Het A
2 54T_GI
3 31T_GII
4 40T_GII
 
Figure 1 
a,b) The H1047R mutation in the PIK3CA gene in a patient with grade IV glioma. This mutation involved a nucleotide change from A>G at 
position 3140 of the gene which was detected by PGM. c) The result was validated using Sanger sequencing which confirmed the mutation, 
PIK3CA c.3140 A>G in this patient. 
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and E556V in PDGFRA. Two patients with Grade I 
glioma showed mutations in KDR, MLH1, MET, and 
PTPN11. Mutations in BRAF, TP53, IDH1, PIK3CA, 
KDR and KIT genes were identified in those with 
Grade II gliomas. In addition, an insertion of A at 
position 149453048 of chromosome 5 of the CSF1R 
(c1061_1061 ins A) gene was identified in one patient. 
For the Grade III patients, four missense mutations 
were identified in the KDR, CSF1R, MET, and TP53 
genes. A frameshift mutation in the PTEN 
(c1371_1373 del A) gene was also identified in 
another patient. Six missense mutations were detected 
in KDR and BRAF, 2 in TP53, PIK3CA, and PDGFRA 
in the Grade IV glioma patients. The H1047R 
mutation in the PIK3CA gene in a patient with grade 
IV glioma involved a nucleotide change from A>G at 
position 3140 of the gene which was detected by PGM 
(Table 1a, b). 
In total, three mutations were predicted to be 
pathogenic. These are the mutations in PTPN11 
(E69K, NN: 0.6476), BRAF (V600E, NN:0.8083), and  
TP53 (E154K, NN:0.6886). The effects of these 
mutations on the protein functions were predicted 
using PolyPhen-2 software. It showed that these 
mutations might lead to protein damage with scores of 
0.970, 0.971, and 0.996 respectively. Mutations in the 
MLH1, MET, KDR, KIT, TP53 (D149E and V157F), 
IDH1, PIK3CA, and PDGFRA were validated using 
Sanger sequencing (Figure 1c). However, Sanger 
sequencing is not sensitive to detect mutations with 
reduced frequency of mutant alleles. Mutation in the 
PTPN11 and TP53 (E154K), could not be detected 
using this technique. The mutant allele’s frequency in 
the PTPN11 was 9%, and samples with TP53 (E154K) 
mutations showed 24 to 26%. 
PTEN deletion could not be validated using the 
Taqman® Mutation Detection Assay due to low variant 
coverage which is 73. We also failed to validate the 
CSF1R insertion using this technique despite the high 
variant coverage which is between 470-1603. MRI 
scan images of selected samples with their 
corresponding sequencing results were shown as in 
Figure 2. 
 
 
  
 
Figure 2 
MRI scan images of selected samples with their corresponding sequencing results. (a) A recurrent pilocytic astrocytoma of the left optic 
nerve in which the tumour bulk (arrow) occupied the whole retro-orbital region. (b) Minimal enhancement seen in a post-gadolinium 
contrasted MRI image of a left frontal fibrillary astrocytoma lesion (arrow). (c) A large heterogeneous lesion with central necrotic area 
(arrow) seen in the left temporo-occipital region of a newly diagnosed GBM. (d) A recurrent right frontal oligodendroglioma (arrow). (e) 
Grade 3 anaplastic glioma with clear cell ependymoma was confirmed from the tumour sample excised from the left basal ganglia (arrow). 
(f) Huge recurrent left frontal anaplastic oligodendroglioma (WHO grade 3) (arrow) was seen impinging the lateral ventricles. (g) Lesion at 
right ventricle with increased signal intensity (arrow) of patient 74T was confirmed as grade 3 anaplastic ependymoma. It was not possible 
to correlate between the genotype and phenotype since the number of samples is too small. 
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Discussion 
 
The Sanger sequencing approach has been employed 
for more than 30 years to detect mutations in many 
diseases including cancers [20,21. Nevertheless, the 
Sanger method is time consuming and multiple genes 
cannot be sequenced simultaneously. Cancer is a 
complex disease that involves multiple gene 
rearrangements and mutations. 
Therefore, the third-generation sequencing platform 
could be the method of choice for mutational 
screening in cancers due to its capability to sequence 
multiple genes simultaneously and less time 
consuming [14]. We employed the Ion Torrent 
Personal Genome Machine (PGM) in combination 
with the Ion AmpliSeq Cancer Panel to analyse 16 
gliomas from different grades and identified a total of 
14 mutations. The KDR gene mutation (Q472H) was 
observed in all glioma grades and ten out of the 16 
patients harbor this mutation. The KDR or VEGF gene 
is a major growth factor for endothelial cells and plays 
a role in angiogenesis, vascular development, vascular 
permeability, and embryonic hematopoiesis [22]. 
Given that VEGF is a pro-angiogenesis factor hence a 
crucial role in pathogenicity and metastasis [23], this 
mutation was expected to be seen more frequently in 
the high grade compared to the low grade gliomas. 
However, the occurrence of the KDR mutation as the 
sole mutation was seen in all grades i.e. in GI 
(21T_GI), GII (69T_GII), GIII (108_GIII), and GIV 
(2T_GIV) patients. In addition, a GIII glioma patient 
(7T_GIII) had only PTEN mutation. These solitary 
mutations may not be the direct cause of glioma in 
these patients as cancer is a multistep process that 
involves multiple genes abnormalities. The hotspot 
cancer panel that we used in this study only contain 44 
cancer-related genes. Thus, we could not exclude the 
possibility that there are other key genes that involved 
in the pathogenesis of glioma that are not represented 
in this panel. The heterogeneity and the diffusive 
nature of glioma cells possess a great challenge in 
order to extract pure biology molecules without being 
contaminated by normal or stromal tissues. Here, we 
performed frozen sections for confirmation of the 
tumour resection. Only patients with 80% tumour cells 
were enrolled in this study to ensure representative of 
cancer tissues. 
The TP53 gene is essential for the metabolic and 
angiogenesis processes in the glioma tumourigenesis 
[24-25]. Three mutations (D149E, E154K, and 
V157F) in the TP53 gene were identified, of which 2 
were novel mutations (D149E and E154K). However, 
only the E154K mutation was pathogenic with an NN 
output of 0.7171. This mutation is located within the 
domain that is crucial for TP53 activity, which 
includes interaction with HIPK1, AXIN1, and E4F1. 
The mutant residue may affect the protein function in 
several ways. First, the mutant residue leads to 
changes in the protein charge, which subsequently 
could cause repulsion between residues in the protein 
core. Additionally, this could also interrupt the ionic 
interaction between the residues in the protein core, 
reducing the catalytic activity of the protein. Second, 
the mutant residue may differ in size when compared 
to the wild-type sequence causing it to reside 
incorrectly in the core protein. Consequently, a 
different hydrogen bond will be made as a result of the 
incorrect position of the mutant residue. Both aspects 
may diminish the interaction with key proteins 
involved in TP53 functions. The patient (31T_GII) 
who carried this mutation is a Malay male aged 40 
years, and had a fibrillary astrocytoma located at the 
deep left frontal lobe.  We also detected the BRAF 
(V600E, pathogenic) mutation in this patient who is 
still alive after a year of diagnosis. In contrast, a 
Chinese patient aged 61 years with GBM at the right 
temporal lobe (8T_GIV) also hadTP53 (E154K) and 
BRAF (V600E) mutations but died after 8.5 months of 
diagnosis. Although both patients carried the same 
mutations, the type of glioma is most likely to 
determine the survival rate of the patients. Another 
patient (98T_GII) who had mutations in BRAF 
(V600E), KIT (M541L) and KDR (Q472H) genes is 
still surviving seven years after being diagnosed with 
pleomorphic xanthomatous astrocytoma (PXA). In 
comparison, one patient with type IV glioma 
(2T_GIV) who carried the non-pathogenic KDR 
(Q472H) mutation died at 0.3 months following 
diagnosis of GBM at the deep left parietal lobe of the 
brain. There was no other mutation identified in this 
patient. The patient (7T_GIII) with a frameshift 
mutation (c1373_1373 del A) in the PTEN gene died 
at the age of ten years, one month after being 
diagnosed with glioma at the left basal ganglia of the 
brain. PTEN is a tumour suppressor gene and is 
involved in modulating cell cycle progression and cell 
survival by the PI3K-AKT/PKB signaling pathway. 
The sample size is rather small to perform a genotype-
based correlation analysis with outcome. Also the 
difficulty in getting normal brain samples as a 
comparison. 
The frameshift mutation in the CSF1R gene, which is 
also a novel mutation, was identified in two patients, 
one with Grade II and another with Grade III glioma. 
CSF1R is a cytokine that controls the production and 
differentiation of macrophages hence is not related to 
the pathway involved in glioma. The E556V mutation 
in the PDGFRA gene is also a novel mutation that was 
identified in a patient with GIV glioma. PDGFRA is a 
transmembrane protein that consists of 5 
immunoglobin-like repeats in the extracellular domain 
and intracellular tyrosine-kinase domain [26]. 
Activation of the PDGFRA receptor by its ligand 
results in signal transduction of the downstream 
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pathways such as MAP kinase, PI3-kinase/AKT and 
JAK/STAT1 [26]. These pathways play a major role 
in cellular proliferation, differentiation, invasion, and 
survival. The patient (10T_GIV) is a Chinese man, 
aged 64 years with GBM at the left temporo-occipital 
lobe of the brain. We could not retrieve the survival 
rate of this patient as he had defaulted follow-up.  
A missense mutation was identified in the MLH1 gene 
(V384D) in one of the grade I glioma patients 
(54T_GI, 27 years old). MLH1 mutations have been 
shown to be strongly associated with inherited Lynch 
syndrome and also Turcot syndrome [27]. Deimling 
and colleagues performed sequencing of exon 15 of 
the BRAF gene on 1320 brain tumours and found that 
93 out of 96 mutations detected were of the V600E-
type [28]. The study reported that 66% of the BRAF 
V600E variant was found in grade II pleomorphic 
xanthoastrocytomas (PXA). One other study detected 
BRAF V600E mutation in 12 out of 20 (60%) patients 
with WHO Grade II PXA [29]. In our study, two out 
of four patients (50%) with grade II tumours harbored 
the BRAF V600E variant. The studies on the BRAF 
V600E variant have shown that this mutation could be 
a promising molecular biomarker and could also be 
potentially targeted for therapy [29]. 
Mutation in the PIK3CA gene has been shown to be 
associated with GBM, oligodendrogliomas, and 
several other brain tumour types [30,31]. Two patients 
were identified with PIK3CA (H1047R) variant i.e. 
one with oligodendroglioma (40T_GII) and the other 
with GBM (10T_GIV). High frequency of the IDH1 
(R132H) variant (66-100%) was present in 
oligodendrogliomas and oligoastrocytomas in several 
populations such as in Germany and USA [32-35].  A 
specific antibody against this variant has been 
developed hence IDH1 could be a reliable diagnostic 
tool to distinguish between these types of brain tumour 
from the other forms [36]. However, the frequency of 
this mutation in our population is low (1/16) patients 
compared to other populations. It is noted that 
mutations in the RB1 gene was absent in all patients 
studied. This could be due to the cancer panel only 
focuses on nine common mutations in the RB1 gene. 
Further mutational analysis in genes commonly 
involved in glioma can be performed using target-
resequencing or whole exome sequencing. We 
compared our results with The Cancer Genome Atlas 
(TCGA) to observe whether there are similarities or 
differences between our glioma patients and TCGA 
samples [37]. Mutation Significance (MutSig) has 
identified 8 significant genes that involve in 
glioblastoma which are TP53, PTEN, ERBB2, 
PIK3R1, NF1, EGFR, RB1 and PIK3CA. Out of these 
eight significant genes, only mutations in PTEN, TP53 
and PIK3CA were observed in our study. We 
identified ten genes in our cohort study and from these 
ten genes, only six genes were in concordance with the 
TCGA database; MLH1, MET, PTPN11, TP53, 
PIK3CA and PDGFRA. Nevertheless, most of the 
identified mutations differ from the TCGA database in 
term of the types and positions, except for the E69K 
mutation in the PTPN11. This suggests that the 
potential causes of glioma in Malaysian population 
could be contributed by different genetic alterations 
compared to the Caucasian population. However, 
these observations need to be verified in a larger 
sample size (n = 206 in TCGA).  
In total, ten missense mutations were validated using 
Sanger sequencing. Two mutations PTPN11 (E69K) 
and TP53 (E154K)] could not be detected using 
Sanger sequencing due to the low frequency of the 
mutated alleles (E69K with a mutant allele frequency 
of 9% and E154K with a mutant frequency of 24%-
26%). We designed a probe for the TaqMan® Mutation 
Detection Assay based on the small deletion and 
insertion detected by the Ion Torrent. For PTEN A 
deletion, the result showed that there was no deletion 
and the gene was homozygous wild type. 
Subsequently, we did Sanger sequencing to further 
confirm this mutation and we detected the AA deletion 
instead of the A deletion. Sanger sequencing or 
TaqMan® Mutation Detection Assay may not be 
sufficient to validate the presence of the mutated 
alleles that exist in low copy number (variant coverage 
= 73, Table 3). Therefore, in order to correctly validate 
these mutated alleles, copy number variation 
experiment needs to be conducted to fulfill the given 
validation process. We also could not validate the 
CSF1R A insertion using both Sanger sequencing and 
TaqMan® Mutation Detection Assay although the 
variant coverage of mutant and wild type is about 50%. 
Other sequencing platforms such as MiSeq or NextSeq 
could be used in order to validate this mutation. 
 
Conclusion 
 
In conclusion, we have successfully identified 14 
mutations (four novel and three pathogenic) in 16 
glioma samples by utilizing the PGM platform. The 
KDR gene mutation was the most common alteration 
and was present in all grades in our cohort of patients. 
PGM has opened a new era in mutation screening 
since it offers a robust and faster method for 
sequencing analysis. In conclusion, PGM in 
combination with the AmpliSeq Cancer Panel could 
potentially offer a better molecular diagnosis for 
glioma and any other cancers. 
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